Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director · President & CEO | October 12, 2026 | October 13, 2026 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director | February 08, 2023 | February 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,544 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-12 · Exercise / conversion · Acquired 7,500 · Balance 286,044 Row 2 · 2026-10-12 · Sale · Disposed 7,500 · Balance 278,544 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2027-02-28 | Direct | 141,745 |
Reported balance
After 2026-10-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-12 · Exercise / conversion · Disposed 7,500 · Balance 141,745 |
| Common StockSEC Table I · non-derivative | Indirectby Trust 1. Beneficial Ownership disclaimed. | 2,083 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,083 F1: Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. |
| Common StockSEC Table I · non-derivative | Indirectby Trust 2. Beneficial Ownership Disclaimed. | 2,083 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,083 F2: Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
F2: Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
Gamida Cell Ltd.
Report date February 08, 2023 · Filed February 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 96,500 |
Ending reported balance
After 2023-02-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-08 · Grant · Acquired 28,300 · Balance 82,300 F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Row 2 · 2023-02-08 · Grant · Acquired 14,200 · Balance 96,500 F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-02-07 | Direct | 56,600 |
Reported balance
After 2023-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-08 · Grant · Acquired 56,600 · Balance 56,600 F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-02-07 | Direct | 28,300 |
Reported balance
After 2023-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-02-08 · Grant · Acquired 28,300 · Balance 28,300 F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date.
F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 17, 2023 22:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 3,230 | $44.13 | $142,539.90 |
DisclosureSEC source: 0001127602-23-005912 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,182 F1 · kind: The reporting person is reporting the withholding of shares of common stock to satisfy the reporting persons withholding obligations in connection with the vesting of Restricted Stock Units vested on February 16, 2023 and does not represent a sale by the reporting person. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 00:15 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 28,300 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008530 · doc4.xml · derivative · entry 4 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 Underlying: Ordinary Shares · 28,300 shares Expires 2033-02-07 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 00:15 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 56,600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008530 · doc4.xml · derivative · entry 3 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,600 Underlying: Ordinary Shares · 56,600 shares Expires 2033-02-07 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 00:15 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008530 · doc4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,500 F1 · shares: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 11, 2023 00:15 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 28,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008530 · doc4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,300 F1 · shares: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:59 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-23-001809 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,691 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:59 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $42.43 | $424,300.00 |
DisclosureSEC source: 0001127602-23-001809 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,412 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:59 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $9.65 | $96,500.00 |
DisclosureSEC source: 0001127602-23-001809 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-23-001067 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,691 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $44.24 | $442,400.00 |
DisclosureSEC source: 0001127602-23-001067 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,412 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $9.65 | $96,500.00 |
DisclosureSEC source: 0001127602-23-001067 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 21, 2022 Filed Aug 11, 2023 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-23-022368 · form4.xml · derivative · entry 9 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,691 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Aug 11, 2023 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $43.92 | $439,240.00 |
DisclosureSEC source: 0001127602-23-022368 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 406,412 F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 21, 2022 Filed Aug 11, 2023 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $9.65 | $96,500.00 |
DisclosureSEC source: 0001127602-23-022368 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-026921 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,691 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $39.30 | $392,970.00 |
DisclosureSEC source: 0001127602-22-026921 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,412 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 22:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $9.65 | $96,500.00 |
DisclosureSEC source: 0001127602-22-026921 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-026333 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,691 Underlying: Common Stock · 10,000 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $40.89 | $408,900.00 |
DisclosureSEC source: 0001127602-22-026333 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $9.65 | $96,500.00 |
DisclosureSEC source: 0001127602-22-026333 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:34 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-058390 · doc4.xml · derivative · entry 2 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2032-11-17 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on February 1, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:34 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058390 · doc4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 F1 · shares: Represents a restricted share unit award, which shall vest on November 1, 2023, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 792 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · derivative · entry 8 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,691 Underlying: Common Stock · 792 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 9,208 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · derivative · entry 7 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,208 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 792 | $42.17 | $33,398.64 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · nonDerivative · entry 4 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 792 | $9.65 | $7,642.80 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 9,208 | $42.17 | $388,301.36 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 9,208 | $7.96 | $73,295.68 |
DisclosureSEC source: 0001127602-22-024962 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-024243 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $47.86 | $478,600.00 |
DisclosureSEC source: 0001127602-22-024243 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 20:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-024243 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-023712 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $50.40 | $504,000.00 |
DisclosureSEC source: 0001127602-22-023712 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-023712 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:33 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | PurchaseOrdinary Shares | 50,000 | $1.55 | $77,500.00 |
DisclosureSEC source: 0001209191-22-052257 · doc4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · price: The reporting person purchased ordinary shares of the Issuer at a price of $1.55 per share in an underwritten public offering by the Issuer, which closed on September 30, 2022. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-022778 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $51.42 | $514,200.00 |
DisclosureSEC source: 0001127602-22-022778 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-022778 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-022237 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $49.11 | $491,100.00 |
DisclosureSEC source: 0001127602-22-022237 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,089 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-022237 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 18, 2022 Filed Jan 3, 2023 21:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GiftCommon Stock | 3,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000117 · form5.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,412 Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-021384 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $50.11 | $501,100.00 |
DisclosureSEC source: 0001127602-22-021384 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,124 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-021384 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-020353 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $41.26 | $412,600.00 |
DisclosureSEC source: 0001127602-22-020353 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,124 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $7.96 | $79,600.00 |
DisclosureSEC source: 0001127602-22-020353 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-22-019558 · form4.xml · derivative · entry 5 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,208 Underlying: Common Stock · 10,000 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:50 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $40.49 | $404,900.00 |
DisclosureSEC source: 0001127602-22-019558 · form4.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,472 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on December 22, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.